2021 FDA Endocrinology Approvals: Novel Small Molecules Deep Dive

By Vinicius Texeira.

Reviewed by Dennis X. Hu.

Edited by Lauren C. Smith.

Sunday June 5, 2022

8 mins read

In 2021, the FDA approved two new drugs for endocrinology-related indications, including severe hypoglycemia in diabetes, and chronic kidney disease (CKD) associated with type 2 diabetes. This article and slide deck explores each in more detail, including but not limited to their:

target rationale
discovery
disease context
original patents
key clinical data
pharmacokinetics
industry history

2021 FDA Endocrinology Approvals: Novel Small Molecules Deep Dive

Upgrade Membership to Download Slide Deck

this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.

RECENT ARTICLES

2021 First-in-Class Large Molecule Drug Approvals (Pt. III)June 26, 2022
May 2022 Molecules of the Month Runners UpJune 24, 2022
Shaken by An Unexpected Patient ConnectionJune 20, 2022
Molecules of the Month – May 2022June 18, 2022
Drug Hunter In-Person EventsJune 16, 2022
Acceleron’s TGF-beta Ligand Trap, Trillium’s SIRP-alpha Fusion Proteins, and Eight Other Large Molecules Acquired in 2021June 10, 2022

DRUG DISCOVERY RESOURCES

JOIN SUBSCRIBERS from